The correlation between different biomolecular breast cancer subtypes frequency and the menstrual state


Cite item

Full Text

Abstract

The dependence of the biomolecular subtype’s frequency from the reproductive state among the 850patients treated in the FSBD «RNIOI» Ministry of Health of RF in the period of2010-2013 was analyzed. By the St. Gallen’s recommendations they were divided into 4 groups by biological subtypes, and then, into 3 subgroups by the reproductive state. According to our results the biomolecular subtype development directly depends from women menstrual state. Totally the luminal B subtype was the most frequent (59,9%) and the Her2neu + subtype on the contrary (7,4%) (p < 0,05), and the majority of the patients were postmenopausal (52,4%) (p < 0,05). The part of the hormone-positive cancer (76,4%) prevails under the hormone-negative (23,6%) in all groups (p < 0,05), but in the reproductive group more than in others (79,8% against 20,2%). Consequently the Her2neu + and TNC frequency in these groups were the less (p < 0,05). In the postmenopausal group Her2neu + subtype was less common (7% against 9% in premenopausal group) (p < 0,05), but TNC on the contrary (18% against 12,8% in reproductive group) (p < 0,05). The luminal B subtype in premenopausal group was less common than in others (55,9% against 67,5% in reproductive group) (p < 0,05). Whereas the luminal A and Her2 + more frequent (19,3% against 12,3% in reproductive group and9% against 7% and 7,4% correspondingly) (p < 0,05). Thus, only TNC keep steadily growing by changing from reproductive state to postmenopausal. However, the tendency lines of other biomolecular subtypes frequency differ crucially. They have peaks in the premenopausal period and differently directed tendencies to the baseline after it. In order to this we estimate the premenopausal period as a special for the luminal and HER2neu + breast cancer subtypes development risk.

About the authors

O. I Kit

Rostov Scientific Research Institute of Oncology

344037, Rostov-on-Don, Russian Federation

Yuliana S. Shatova

Rostov Scientific Research Institute of Oncology

Email: shat5@rambler.ru
MD, PhD 344037, Rostov-on-Don, Russian Federation

S. S Todorov

Rostov Scientific Research Institute of Oncology

344037, Rostov-on-Don, Russian Federation

T. N Gudtskova

Rostov Scientific Research Institute of Oncology

344037, Rostov-on-Don, Russian Federation

References

  1. Семиглазов В.Ф. Новые подходы к лечению рака молочной железы. Вопросы онкологии. 2013; 59 (3): 288-91.
  2. Семиглазов В.Ф. Стратегические и практические подходы к решению проблемы рака молочной железы. Вопросы онкологии. 2012; 58 (2): 148-52.
  3. Parker J.S., Mullins M., Cheang M.C.U., Leung S., Voduc D., Vickery T. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 2009; 27: 1160-7.
  4. Perou C.M., Sorlie T., Eisen M.B., Rijn M., Jeffrey S.S., Rees C. A. et al. Molecular portraits of human breast tumors. Nature. 2000; 406: 747-52.
  5. Blows F.M., Driver K.E., Schmidt M.K., Broeks A., Leeuwen F.E., Wesselling J. et al. Subtyping of breast cancer by immnohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLosMed. 2010; 7: 279.
  6. Cheang M.C.U., Chia S.K., Voduc D., Gao D., Leung S., Snider J. et al. Ki 67 index, HER-2 status, and prognosis of patients with luminal B breast cancer. J. Nat. Cancer Inst. 2009; 101: 736-50.
  7. Hugb J., Hanson J., Cheang M.C., Nielsen T.O., Perou C.M., Dumontet C. et al. Breast cancer subtypes and response to doxetaxel in node-positive breast cancer: use in immunohistochemical definition in the BCIRG 001tTrial. J. Clin. Oncol. 2009; 27: 1168-76.
  8. Kwan M.L., Kushi L.H., Weltzien E., Maring B., Kutner S.E., Fulton R.S. et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res. 2009; 11:R31 (doi: 10.1186/bcr2261); 11 (3).
  9. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K. et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. J. A. M. A. 2006; 295: 2492-502.
  10. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA. 2001; 98: 10869-74.
  11. Berry D.A., Cirrincione C., Henderson I.C., Citron M.L., Budman D.R., Goldstein L.J. et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. J. A. M. A. 2006; 295(14):1658-67.
  12. Harris L.N., Broadwater G., Lin N.U., Miron A., Schnitt S.J., Cowan D. et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res. 2006; 8: 66.
  13. Nguyen P.L., Taghian A.G., Katz M.S., Niemierko A., Abi Raad R.F., Boon W.L. et al. Breast cancer subtype approximated by eatrogen receptor, progesterone receptor, and HER- 2 is associated with local and distant recurrence after breast-conserving therapy. J. Clin. Oncol. 2008; 26: 2373-8.
  14. Rouzier R., Perou C.M., Symmans W.F., Ibrahim N., Cristofallini M., Anderson K. et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 2005; 11 (16): 5678-85.
  15. Wo J.Y., Taghian A.G., Nguyen P.L, Raad R.A., Sreedhara M., Bellon J.R. et al. The association between biological subtype and isolated regional nodal failure after breast-conserving therapy. Int. J. Radiat. Oncol. Biol. Phys. 2010; 77: 188-96.
  16. Vladimirova L.Y., Kit O.I. Long-term results of capicitabine application in metastatic breast cancer patients. J. Clin. Oncol. 2012; 30 (15S, part I of II): 800S, E11558.
  17. Одарченко С.П., Болюх Д.Б., Одарченко П.А., Тамилович А.В., Корчистый В.И. Иммуногистохимические особенности рака молочной железы в популяции женского населения Подольского региона Украины. В кн.: Материалы IX Международной ежегодной конференции «Проблемы диагностики и лечения рака молочной железы». Белые ночи Санкт- Петербурга, 18-20 июня 2012. СПб, 2012: 100-1.
  18. Kurian A.W., Fish K., Shema S.J., Clarke C.A. Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res. 2010; 12: 99.
  19. Сметник В.П., Тумилович Л.Г. Неоперативная гинекология. СПб: Сотис; 1995.
  20. Romero Q., Bendahl P.-O., Klintman M., Loman N., Ingvar Ch., Ryden L. et al. Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies. BMC Cancer. 2011; 11: 341.

Copyright (c) 2014 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies